172 related articles for article (PubMed ID: 35023192)
1. Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
Nussbaum PE; Nussbaum LA; Torok CM; Patel PD; Yesavage TA; Nussbaum ES
J Clin Pharm Ther; 2022 Jun; 47(6):826-831. PubMed ID: 35023192
[TBL] [Abstract][Full Text] [Related]
2. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
Roque A; Odia Y
CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
[TBL] [Abstract][Full Text] [Related]
3. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
[TBL] [Abstract][Full Text] [Related]
4. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
[TBL] [Abstract][Full Text] [Related]
5. Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations.
Juratli TA; Jones PS; Wang N; Subramanian M; Aylwin SJB; Odia Y; Rostami E; Gudjonsson O; Shaw BL; Cahill DP; Galanis E; Barker FG; Santagata S; Brastianos PK
Cancer; 2019 Sep; 125(17):2910-2914. PubMed ID: 31314136
[TBL] [Abstract][Full Text] [Related]
6. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF
White PS; Pudusseri A; Lee SL; Eton O
Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135
[TBL] [Abstract][Full Text] [Related]
7. TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants.
Dawoud FM; Naylor RM; Giannini C; Swanson AA; Meyer FB; Uhm JH
Clin Neurol Neurosurg; 2020 Sep; 196():106059. PubMed ID: 32682222
[No Abstract] [Full Text] [Related]
8. Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
Wu ZP; Wang YL; Wang LC; Liu ZY; Fan RR; Zan X; Liang RC; Yang JL; Zhou LX; Xu JG
World Neurosurg; 2023 Dec; 180():e117-e126. PubMed ID: 37683921
[TBL] [Abstract][Full Text] [Related]
9. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
11. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
12. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
14. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
Dummer R; Hauschild A; Santinami M; Atkinson V; Mandalà M; Kirkwood JM; Chiarion Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Lesimple T; Plummer R; Dasgupta K; Gasal E; Tan M; Long GV; Schadendorf D
N Engl J Med; 2020 Sep; 383(12):1139-1148. PubMed ID: 32877599
[TBL] [Abstract][Full Text] [Related]
15. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
Meng P; Koopman B; Kok K; Ter Elst A; Schuuring E; van Kempen LC; Timens W; Hiltermann TJN; Groen HJM; van den Berg A; van der Wekken AJ
Lung Cancer; 2020 Aug; 146():358-361. PubMed ID: 32534795
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
Calvanese F; Jacquesson T; Manet R; Vasiljevic A; Lasolle H; Ducray F; Raverot G; Jouanneau E
Front Endocrinol (Lausanne); 2022; 13():882381. PubMed ID: 35757402
[TBL] [Abstract][Full Text] [Related]
17. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
[TBL] [Abstract][Full Text] [Related]
18. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
[TBL] [Abstract][Full Text] [Related]
19. Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma.
Lin AL; Tabar V; Young RJ; Geer EB
Pituitary; 2023 Aug; 26(4):482-487. PubMed ID: 37428397
[TBL] [Abstract][Full Text] [Related]
20. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
[No Abstract] [Full Text] [Related]
[Next] [New Search]